ondasdechoque.org
PT-BR

Musculoskeletal pain: evidence varies by indication · Review · 2023

Which kinds of muscle and joint pain may shockwave help?

In this review, results depended on the problem and the comparison. In one trial, outer hip pain eased more with shockwave than with a steroid injection after a year; in another, athletes with groin pain returned to football sooner. Studies of low-back function and carpal tunnel syndrome showed little difference.

studies included
98
people in the outer-hip trial (shockwave vs steroid injection)
104
athletes in the groin-pain study
44

Good to know: A broad overview of 98 studies across many conditions, selected by the authors.

De la Corte-Rodríguez H, Román-Belmonte JM, Rodríguez-Damiani BA, et al. Healthcare (Basel), 2023 · Read the paper ↗

How this study worked

One answer
A review gathers earlier studies to answer one question. Illustration, not to scale.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

Who took part

People with tendon problems, heel pain, back pain, knee arthritis, bone-healing and blood-vessel problems, and carpal tunnel syndrome, across many studies.

Side effects

Bruising is more likely at higher strengths, and treatment can be uncomfortable. One Achilles tendon tear two weeks after a session is reported; it is unclear whether shockwave caused it.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

What the full paper reports.

Multiple tendon disorders, plantar fasciitis, axial pain, knee osteoarthritis, bone healing and vascular disorders, and carpal tunnel syndrome. Participants recur across cited reviews; there is no independent aggregate patient count.

Selected comparative findings1 reported outcome
01
As reported in the article

Selected comparative findings

Qualitative finding

Selected examples: a 104-person trochanteric trial reported 12-month VAS 37.1 versus 55.0 after injection comparison; a 44-athlete pubic-pain study reported return to football at 73.2 versus 102.6 days. Important null findings include low-back function, short-term patellar placebo comparisons, knee function versus PRP and carpal-tunnel comparisons with steroid injection. No common effect or certainty estimate can be derived.

Analysis details and source

Qualitative extraction preserves the source scope.

Benefits that did not persist1 reported outcome
02
As reported in the article

Benefits that did not persist

Qualitative finding

Ten-person coccydynia study improved at four weeks and two months but not seven months; carpal-tunnel add-on review found only transient four-week benefit. A 34-person coccydynia series reported VAS 9.6±0.5 to 3±3.2 at six months without a control.

Analysis details and source

Qualitative extraction preserves the source scope.

Harms reporting1 reported outcome
03
As reported in the article

Harms reporting

Qualitative finding

Bruising is associated with higher intensity; treatment discomfort and a reported Achilles rupture two weeks after a session are discussed, with causality uncertain. No pooled adverse-event denominator is supplied. Absence of significant events in many reports is not a measured zero-risk rate.

Analysis details and source

Qualitative extraction preserves the source scope.

How treatment was delivered
HARMS & TOLERABILITY

Bruising is associated with higher intensity; treatment discomfort and a reported Achilles rupture two weeks after a session are discussed, with causality uncertain. No pooled adverse-event denominator is supplied. Absence of significant events in many reports is not a measured zero-risk rate.

LIMITS OF THE ANALYSIS

Subjective selection and heterogeneous controls limit conclusions. Table 3 lists nine 1− entries although the abstract says eight; avascular hip necrosis and femoral-head osteonecrosis overlap conceptually. Grades are not an outcome-specific GRADE assessment. Reference 79 is the historical Ogden overview, not a modern pooled trial analysis. No external funding or conflicts declared.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Subjective selection and heterogeneous controls limit conclusions. Table 3 lists nine 1− entries although the abstract says eight; avascular hip necrosis and femoral-head osteonecrosis overlap conceptually. Grades are not an outcome-specific GRADE assessment. Reference 79 is the historical Ogden overview, not a modern pooled trial analysis. No external funding or conflicts declared.
Research review

Source-linked critical reading

clinical synthesis

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Narrative review searching five databases on 11 August 2023. It reports 3,517 records, 149 screened, 115 considered relevant and 98 included, prioritizing higher-level studies. The stated exclusion count of 34 does not explain the transition from 115 to 98. No new pooled analysis was performed.

Participants and setting

Multiple tendon disorders, plantar fasciitis, axial pain, knee osteoarthritis, bone healing and vascular disorders, and carpal tunnel syndrome. Participants recur across cited reviews; there is no independent aggregate patient count.

Treatment

Focused and radial modalities are distinguished. Table 2 gives condition-specific session and pulse ranges, but the authors acknowledge no consensus. General dosing statements and table recommendations differ; these are review suggestions, not a validated universal prescription.

Comparison

Placebo, exercises, physical modalities, injections and surgery vary by indication. Shared rehabilitation and differences between radial and focused treatment complicate cross-study comparisons.

Outcomes and timing

Pain and function dominate, with return to sport, imaging, union and electrophysiology in specific indications. Follow-up ranges from weeks to years; imaging improvement need not track symptom improvement.

What the results show

Selected examples: a 104-person trochanteric trial reported 12-month VAS 37.1 versus 55.0 after injection comparison; a 44-athlete pubic-pain study reported return to football at 73.2 versus 102.6 days. Important null findings include low-back function, short-term patellar placebo comparisons, knee function versus PRP and carpal-tunnel comparisons with steroid injection. No common effect or certainty estimate can be derived.

Harms

Bruising is associated with higher intensity; treatment discomfort and a reported Achilles rupture two weeks after a session are discussed, with causality uncertain. No pooled adverse-event denominator is supplied. Absence of significant events in many reports is not a measured zero-risk rate.

Limits and disclosures

Subjective selection and heterogeneous controls limit conclusions. Table 3 lists nine 1− entries although the abstract says eight; avascular hip necrosis and femoral-head osteonecrosis overlap conceptually. Grades are not an outcome-specific GRADE assessment. Reference 79 is the historical Ogden overview, not a modern pooled trial analysis. No external funding or conflicts declared.

Application to care

An orientation map for clinicians, requiring indication-specific appraisal. Broad claims of safety and efficacy should not replace the null and uncertain findings described in the body.

What remains to be tested

Conduct transparent condition-specific systematic reviews, reconcile selection counts, separate modalities and co-interventions, and use blinded trials with prespecified function, pain, harms and durable follow-up.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal Shock Wave Therapy for the Treatment of Musculoskeletal Pain: A Narrative Review

De la Corte-Rodríguez H, Román-Belmonte JM, Rodríguez-Damiani BA, Vázquez-Sasot A, Rodríguez-Merchán EC. · Healthcare (Basel) · 2023

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →